Pipeline
Inflammasome Inhibitor
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
Dermatology
-
-
GPCR19 Agonist
NuGel
Atopic Dermatitis
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
NuGel
Blocks the root cause of atopic dermatitis to restore skin health and reduce daily discomfort.
-
Competitiveness
Demonstrated both superior efficacy and safety in clinical studies, while offering convenient topical application suitable for long-term management of chronic atopic dermatitis.
-
Market Outlook
The global atopic dermatitis treatment market is projected to grow from approximately USD 13 billion in 2024 to USD 33 billion by 2030.
-
Unmet Needs
Current therapies are often limited by severe side effects or suboptimal efficacy relative to cost, making them unsuitable for long-term use. There remains a strong need for new, safer, and more effective treatment options.
-
Development Status
Completed a Phase IIa clinical trial in Korea and successfully finished Part 1 of the U.S. Phase IIb study under FDA approval. The global Phase IIb Part 2 trial is currently in progress.
-
-
-
GPCR19 Agonist
NuDifin
Diabetic foot ulcer
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
NuDifin
Calms wound inflammation and accelerates the regeneration of new, healthy tissue.
-
Competitive Edge
It promotes faster wound healing compared with existing therapies, shows superior collagen and epidermal regeneration, and can be used safely over the long term in patients with chronic conditions such as diabetes.
-
Market Opportunity
The global market for diabetic foot ulcer treatments is projected to grow from approximately USD 8.8 billion in 2024 to USD 14.4 billion by 2032.
-
Unmet Need
Current treatment options often show limited efficacy, frequent recurrence, and side effects, leading to delayed healing in many patients. There is a strong need for safer therapies that can restore inflammatory balance while accelerating tissue regeneration.
-
Development Status
In preclinical studies, NuDifin has demonstrated wound contraction, de novo collagen formation, and complete epidermal restoration. Its safety profile has been confirmed in a Phase 1 clinical trial, and a Phase 2 clinical trial is currently in planning.
-
-
-
Next-generation
GPCR19 AgonistNuRalin
Atopic Dermatitis
(Topical) -
-
-
-
Next-generation
GPCR19 AgonistNuAreatin
Alopecia Areata
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
NuAreatin
Restores immune balance to reactivate hair follicles and bring new hope to areas of hair loss.
-
Competitiveness
Normalizes scalp immune homeostasis and promotes follicle regeneration, enabling long-term treatment durability superior to existing therapies.
-
Market Outlook
The global alopecia areata treatment market is projected to grow from approximately USD 3.8 billion in 2025 to USD 6.9 billion by 2034.
-
Unmet Needs
Current therapies are limited by side effects, cost, and high relapse rates, leaving major treatment gaps for severe and pediatric patients. Given the autoimmune nature of alopecia areata, there is a strong need for a long-term and safe therapy that focuses on restoring immune balance rather than broad immunosuppression.
-
Development Status
NuAreatin was discovered using Shaperon’s AI-driven AIDEN platform and has demonstrated immunomodulatory efficacy in preclinical studies. Additional non-clinical evaluations are underway in preparation for clinical development.
-
Neurological Disorders
-
-
GPCR19 Agonist
NuCerin
Alzheimer’s Disease
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
NuCerin
A smart little pill designed to reduce neuroinflammation and protect precious memories.
-
Competitiveness
An oral therapy that simultaneously targets amyloid-β (Aβ) and neuroinflammation, the two major causes of Alzheimer’s disease. It can be administered safely for long-term use without risks of brain edema or hemorrhage.
-
Market Outlook
The global Alzheimer’s disease treatment market is projected to grow from approximately USD 6.4 billion in 2025 to USD 31 billion by 2034.
-
Unmet Needs
There is a high demand for a convenient and well-tolerated therapy with fewer side effects and proven efficacy not only in delaying but also in improving cognitive symptoms compared with existing treatments.
-
Development Status
Efficacy has been validated in preclinical studies. Phase I clinical trial Part A has been completed in Korea, and Part B is currently in progress.
-
-
-
GPCR19 Agonist
NuSepin
CVA
-
-
Respiratory Diseases
-
-
GPCR19 Agonist
NuSepin
COVID-19
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
NuSepin
Rapidly alleviates excessive systemic inflammation in severe patients, accelerating recovery to everyday life.
-
Competitiveness
Effectively controls broad-spectrum inflammatory responses, enabling safe use in high-risk patients regardless of COVID-19 viral variants. Its mechanism allows potential expansion to systemic inflammatory diseases such as sepsis and ischemic stroke.
-
Market Outlook
The global market for SIRS therapeutics is projected to grow from approximately USD 1.4 billion in 2025 to USD 3.0 billion by 2035.
-
Unmet Needs
Current therapies for severe COVID-19 remain limited due to the lack of effective anti-inflammatory agents resilient to viral mutations and the serious side effects of existing drugs.
-
Development Status
Received global Phase IIb/III IND approval and completed a global Phase IIb clinical trial for severe COVID-19 patients with support from the Korea Drug Development Fund (KDDF). Indication expansion is currently underway for the treatment of systemic inflammatory response syndrome (SIRS) and ischemic stroke.
-
-
-
GPCR19 Agonist
NuPulin
IPF
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
NuPulin
Breaking the vicious cycle of inflammation-driven pulmonary fibrosis to help you breathe comfortably again.
-
Competitiveness
NuPulin delivers efficacy comparable to existing therapies, while safely improving both pulmonary fibrosis and systemic inflammation without gastrointestinal adverse effects or hepatotoxicity.
-
Market Outlook
The global idiopathic pulmonary fibrosis (IPF) treatment market is projected to grow from approximately USD 3.7 billion in 2024 to USD 5.5 billion by 2030.
-
Unmet Need
Current therapies have limited ability to reverse advanced fibrosis and are often associated with a high risk of liver toxicity. Patients and physicians need new treatment options that can safely and effectively control fibrosis.
-
Development Status
NuPulin has demonstrated efficacy in preclinical studies. It has completed Part A of a Phase 1 clinical trial in Korea, and Part B is currently in progress.
-
NanoMab
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
Hematologic Malignancy
-
-
Anti-PD-L1*CD47
Papiliximab
AML
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
Papiliximab
A new standard in leukemia treatment — achieving both reduced anemia risk and enhanced anti-tumor efficacy.
-
Competitiveness
Papiliximab is a NanoMab-based bispecific antibody that simultaneously blocks PD-L1 and CD47, delivering superior anti-cancer activity without the anemia and other adverse effects commonly seen with conventional antibody therapies.
-
Market Outlook
The global bispecific antibody market is projected to grow from USD 18 billion in 2025 to USD 485 billion by 2034.
-
Unmet Need
Current leukemia treatments face low response rates with PD-L1 monotherapy and anemia caused by CD47-targeted agents. Papiliximab is designed to overcome both challenges, offering an innovative therapeutic option for hematologic malignancies.
-
Development Status
Preclinical studies in rodents and non-human primates have demonstrated strong anti-tumor efficacy and excellent safety, and the program is preparing for Phase I clinical trials in patients with acute myeloid leukemia and other hematologic cancers.
-
Solid Cancer
-
-
Anti-CD3*4-1BB*TAA
Ovizumab
NSCLC
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
Ovizumab
A next-generation tumor-specific immunotherapy that boosts immune cell activity within the tumor microenvironment.
-
Competitiveness
Ovizumab enhances tumor selectivity to minimize toxicity in normal tissues while improving blood-stream stability for balanced safety, potency, and durability. Its modular design enables application across multiple solid-tumor indications.
-
Market Outlook
The immuno-oncology and multi-target antibody markets are rapidly expanding, particularly in solid tumors, driving strong demand for next-generation T-cell-activating platforms.
-
Unmet Need
Existing therapies often suffer from cytokine-release syndrome, off-target toxicity, and limited efficacy or durability. Ovizumab is being developed to address these key limitations.
-
Development Status
At the early preclinical stage, Ovizumab has shown robust tumor-suppressive activity in cancer cell models, demonstrating strong potential as a novel solid-tumor therapy.
-
-
-
Anti-CTLA-4*TAA
Regtizumab
Solid Cancer
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
Regtizumab
Revitalizing anti-tumor immunity while minimizing systemic side effects.
-
Competitiveness
As a precisely engineered NanoMab, Regtizumab exhibits superior tissue penetration and selectively inhibits regulatory T cell function within the tumor microenvironment, enhancing immune activation while reducing systemic toxicity. It also holds strong potential for combination therapy with other immune checkpoint inhibitors.
-
Market Outlook
Immuno-oncology continues to expand rapidly through combination regimens, and Treg-targeted therapeutics represent a highly promising and underserved segment.
-
Unmet Need
Current treatments carry risks of systemic immune-related toxicities and limited efficacy due to resistance. Regtizumab aims to deliver precision immune modulation with improved safety and durability.
-
Development Status
In early preclinical development, Regtizumab has shown restoration of immune activity through selective Treg suppression with a favorable safety profile.
-
-
-
LNP-mRNA
Rbody
Solid Cancer
-
- Development
- Optimization
- Preclinical
- Ph1
- Ph2
Rbody
Improving both treatment outcomes and patient quality of life by reducing dosing frequency and cost.
-
Competitiveness
Unlike conventional antibodies, NanoMabs’ small size enables the creation of LNP-mRNA therapeutics (Rbody). Our optimized NanoMab-based Rbody maintains long in-vivo persistence and high stability even at lower doses, providing significant cost-effectiveness unattainable with traditional antibody drugs.
-
Market Outlook
Excluding vaccines, the global mRNA-based therapeutics market is expected to grow from USD 19.6 billion in 2024 to USD 42.6 billion by 2034.
-
Unmet Need
mRNA-based protein therapeutics still face challenges such as low expression and durability, manufacturing quality control, and safety issues—areas where Rbody offers innovative solutions.
-
Development Status
In preclinical studies, Rbody maintained the same in-vivo half-life as antibodies at less than half the dose, demonstrating strong potential for durable and efficient mRNA-based therapy.
-
